Dosage of Tirzepatide

Recommended Dosage

The recommended starting dose of Tirzepatide is 2.5 mg once weekly as a subcutaneous injection. Follow the dose escalation regimen below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg dose is intended only for treatment initiation and is not for glycemic control.

After 4 weeks, increase the dose to 5 mg once weekly as a subcutaneous injection. If further glycemic control is needed, after at least 4 weeks on the current dose, increase the dose in 2.5 mg increments.

Tirzepatide is administered once weekly at any time of day, with or without meals.

Maximum Dose of Tirzepatide

Adults: 15 mg once weekly as a subcutaneous injection

Pediatric patients: 10 mg once weekly as a subcutaneous injection

Missed Dose of Tirzepatide

If a dose is missed, instruct the patient to take the missed dose as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day. In either case, patients can then resume their usual once-weekly dosing schedule. The day of weekly administration may be changed if necessary, ensuring at least 3 days (72 hours) between doses.

Medication Precautions

1. Before initiating treatment, train the patient and their caregiver on the correct injection technique for the prescribed formulation. After training, if a healthcare professional determines that the administration technique is proper, the patient may self-inject Tirzepatide, except in the following cases:

2. Pediatric patients are not recommended to self-administer Tirzepatide;

3. Visually impaired individuals are not recommended to self-administer Tirzepatide;

4. Instruct patients using Tirzepatide injection vials to select an appropriate syringe for administration (e.g., a 1 mL syringe capable of measuring 0.5 mL or 0.6 mL doses), and to use a new syringe and needle for each injection.

5. Subcutaneous injection sites for Tirzepatide include the abdomen or thigh; the back of the upper arm may be used when injected by another person. Rotate the injection site with each dose.

6. Visually inspect the Tirzepatide solution before use. The solution should be clear, colorless to slightly yellow. Do not use if particles or discoloration are observed.

7. When Tirzepatide is used in combination with insulin, administer them as separate injections and do not mix. Tirzepatide and insulin may be injected in the same body region, but the injection sites should not be adjacent.